The TP63 gene, a member of the TP53 gene family, encodes several isoforms with (TAp63) or without (DNp63) transactivating properties. Whereas the role of p63 in the normal development of squamous epithelia is well established, its function in other cell types remains to be elucidated. Here, we have analysed the expression of TA and DNp63 isoforms in liver cells, by using both primary hepatocytes from wild type and p53-null mice and three human hepatocellular carcinoma (HCC) cell lines, according to the transformation state and the TP53 status of the cells. We observed the expression of DNp63 isoforms only in a p53-null context. On the other hand, the expression of TAp63 isoforms was restricted to the HCC cell lines, whatever the TP53 status. We then studied the expression of TP63 upon genotoxic treatment. When treated with UVB or H 2 O 2 , hepatocytes did not exhibit any change in p63 mRNA level. At the opposite, upon treatment with topoisomerase II inhibitors (doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells. The same treatment did not induce any variation in the expression of DNp63 isoforms, both at mRNA and protein levels. In HCC cell lines, doxorubicin or etoposide treatment also resulted in an increase of TAp63 transcripts only. This increase was accompanied by an increase in the intracellular level of TAp63 alpha protein. In parallel, we observed an upregulation of some p53-target genes related to cell cycle regulation, such as WAF1/CIP1, PIG3, 14-3-3r or GADD45, independently of the TP53 status of cells. In conclusion, we report for the first time that TA and DNp63 alpha proteins are present in liver cells. Furthermore, our results suggest that p63 may partially substitute for wild-type p53, in counteracting uncontrolled liver cell proliferation in response to certain forms of DNA-damage.
The p53 protein plays a major role in the cellular response to various stress signals (Vogelstein et al., 2000) . Among them, genotoxic stress is probably the best documented. Addition of a DNA-damaging agent on cells first results in accumulation of p53 protein, which is able to activate the transcription of genes whose products are involved in cell cycle arrest, DNA repair or apoptosis (Pluquet and Hainaut, 2001) . In more than 50% tumours, cells have lost wild-type p53 activity, due to a complete loss of TP53 gene expression, or to single missense mutations (Hainaut and Hollstein, 2000) . Missense mutations lead in general to the expression of a mutant protein defective for wild-type p53 functions. Cells expressing mutant p53 or p53-null cells often show a decreased chemosensitivity and several reports suggest the inactivation of p53 as a major cause of this property (Mueller and Eppenberger, 1996) .
Liver cancer is the fifth human cancer for incidence and the third for mortality in the world (Parkin et al., 2001) . Hepatocellular carcinoma (HCC), the most common malignant tumour of the liver, has a very bad prognosis (over 95% mortality after 5 years), due in particular to the resistance of HCC cells to chemo-or radiotherapy (Bruix and Llovet, 2002) . TP53 shows a very particular pattern of alterations in HCC. In developing countries with high dietary intoxication by aflatoxin-B1 (AFB1) and high prevalence of chronic hepatitis B or C viral infections, mutations in TP53 gene are frequently observed (53%), with a specific 'hot spot' at codon 249 (p53R249S, AGG to AGT, Arginine to Serine) (Shen and Ong, 1996) . The reason why p53R249S is over-represented in these HCC is still unclear. One hypothesis is that p53R249S is specifically selected during AFB1-induced hepatocarcinogenesis (Montesano et al., 1997; Staib et al., 2003) . In HCC from industrialized countries, where tumour essentially develops from alcohol-generated cirrhosis, TP53 missense mutations are observed in about 25% of samples and the codon 249 does not represent a 'hot spot' codon (Montesano et al., 1997) . Therefore, with the exception of few tumours in which TP53 expression is totally abolished, many HCC from developed countries express p53 under a wild-type form. Tumours with wild-type, mutant or no p53 protein do not appear to differ with respect to their chemo-and radio-sensitivity (Chou et al., 1997) , suggesting that other proteins could be responsible for the response of HCC cells to therapeutic agents.
Among these proteins, p63 and p73, the two other members of the p53 family, could represent good candidates. These proteins share common features with p53. In particular, they have a DNA-binding domain located in the central part of the molecule and a transactivation domain in the N-terminal region. The DNA-binding domain of p63/p73 is 65% identical with that of p53 and, indeed, p63 and p73 are able to activate the transcription of some p53-target genes (Irwin and Kaelin, 2001; Yang et al., 2002) . Recent reports have shown that p63 and p73 also specifically transactivate genes that are not p53 targets Wu et al., 2003) . However, the expression of TP63 or TP73 is strikingly different from that of TP53. First, many isoforms can be expressed from each gene. The use of two different promoters generates two N-terminal isoforms called TA and DN, the second one deleted for the transactivation domain. Furthermore, alternative splicing within the 3 0 end results in several C-terminus isoforms called a, b, g, for p63 and a, b, g, d, e and z for p73 (Irwin and Kaelin, 2001; Yang et al., 2002) . Second, TP63 and TP73 expression profiles in tissues are quite different from TP53. They are only expressed in some tissues, in the differentiation of which they are implicated Benard et al., 2003) . In particular, p63 plays a major role in stratified epithelia. This is illustrated by TP63 knockout mice that are deficient in the development of limbs, epidermis, mammary glands, prostate or urothelial tissue and which die very shortly after birth . In humans, several genetic syndromes where patients exhibit ectodermal dysplasia and limb abnormalities have recently been connected with constitutive missense or nonsense mutations in TP63 gene (van Bokhoven and McKeon, 2002) . If the pathways in which p63 and p73 are involved during developmental process are not elucidated yet, some activities of these proteins have been identified. In particular, p63 and p73 can induce growth arrest and apoptosis in response to some stress signals, two functional properties that they share with p53 Courtois et al., 2004) . Nevertheless, only limited information is available on the mechanisms involved in this response.
In order to investigate a possible role for p63 in the response of hepatocytes to genotoxic insult, we studied the expression of TA and DN isoforms of p63 in mouse hepatocytes and human HCC cell lines submitted to various chemotherapeutic agents. We report here for the first time that TP63 is expressed in liver cells and detected both at mRNA and protein levels. Furthermore, we show that the expression of TA isoforms is increased by two topoisomerase II inhibitors, etoposide and doxorubicin. In contrast, DN isoforms are constitutively expressed only in hepatocytes and HCC cell lines that do not express p53 and their expression is not modified by the treatment. Finally, a constitutive expression of TAp63 is detected in HCC cell lines, but not in primary hepatocytes from wild type or p53-null mice.
Hepatocytes and HCC cell lines express p63 isoforms according to TP53 status Hepatocytes from normal and TP53 knockout adult mice were isolated by in situ collagenase A perfusion and plated in the presence of fetal calf serum. At 3 h after plating, the medium was replaced by a serum-free medium supplemented with insulin, dexamethasone and T3 hormone. After an overnight culture in this medium, only the hepatocytes survive (Gillet et al., 2000) . This corresponds to time 0 of experiment. TP63 expression was determined by RT-PCR, using primer pairs that amplified all isoforms or specific N-or C-terminal fragments (see Table 1 ). Only hepatocytes from TP53 knockout mice expressed detectable levels of p63 mRNA, coding for a single isoform with a DN N-terminus ( Figure 1a , p53À/À, lane 'control') and an alpha C-terminus (data not shown). No variation was observed in TP63 expression during the time of culture.
TP63 expression was further studied in three human HCC cell lines, which differ in TP53 status. The HepG2 cell line expresses wild-type p53, the Mahlavu cell line expresses the liver-specific p53R249S mutant, whereas the Hep3B cell line has no p53, due to a homozygous deletion of TP53. Consistent with the data obtained with mouse hepatocytes, only p53-null Hep3B cells contained detectable levels of DN mRNA. Neither HepG2 nor Mahlavu cells expressed any mRNA for these isoforms. At the opposite, basal expression of TA isoforms was present in all the three cell lines without any treatment (Figure 1b, upper panel, lanes 'control') . Since the analysis of the C-terminus revealed that only the alpha form is present in HepG2 and Mahlavu, we can conclude that TAp63 alpha isoform is expressed in these two cell lines. In Hep3B, the C-terminus corresponding to alpha form seemed to be the main one, but beta and gamma forms were also detectable ( Figure 1b , lower panel, lanes 'control'). The low level of each of these species did not allow us to amplify full-length transcripts and to link one specific C-terminus (alpha, beta or gamma) to the TA and/or the DN N-terminus. We thus studied the expression of TA and DN isoforms at protein level. Out of the four anti-p63 antibodies we tested, only the H-129 polyclonal serum, specific for alpha isoforms, allowed to clearly reveal the endogenous p63 ( Figure 2 ). As expected, TAp63 alpha was detected in all the three cell lines, with a stronger expression in Hep3B cells, whereas DNp63 alpha was only present in Hep3B cells, therefore, in the absence of any p53 (Figure 2 , lanes 'À'). The band observed under the DNp63 alpha is likely nonspecific since it migrated more rapidly than the exogenous DNp63 alpha from transfected cells used as positive control. Moreover, this band was over-represented in Malhavu cells, where no DNp63 mRNA was detected.
Taken together, the results suggest first that the expression of DN isoforms is only possible when p53 protein is absent. This hypothesis is supported by a recent report showing that DNp63 expression is inhi-TP63 gene expression in liver cells A Petitjean et al bited by wild-type p53 in primary cultures of human keratinocytes (Waltermann et al., 2003) . Interestingly, the Mahlavu cell line expressing p53R249S has no detectable DN, like the HepG2 cell line. This suggests that p53R249S may retain the capacity to repress DNp63 expression in human HCC cell lines. The expression of TA isoforms differs between primary hepatocytes from mouse, where they are not detectable, and HCC cell lines, in which they are always found. The discrepancy could be due to the transformed status of HCC cells. Alternatively, it could result from the long-term culture of HCC cell lines.
We also tested the expression of TP73 in Hep3B, HepG2 and Mahlavu cell lines, by determining the mRNA level of TA and DNp73 isoforms, as well as the N-terminus splicing variant DN 0 p73. All of these isoforms were detected in HepG2 and Hep3B but not in Mahlavu cell lines (data not shown). This is not in agreement with the results reported by Ozturk and co-workers. The authors observed a level of TA and DNp73 transcripts in Mahlavu cells similar to that of HepG2 and Hep3B cells (Sayan et al., 2001) . We have no hypothesis to explain this discrepancy. However, our results on TP63 and TP73 expression suggested that these two genes are differentially regulated in hepatocytes, as recently shown in human keratinocytes (Waltermann et al., 2003) .
The expression of TAp63 isoforms is induced by some DNA-damaging agents in hepatocytes and HCC cell lines, independently of their TP53 status Since p63 and p73, like p53, were found to play a role in the cellular response to some DNA-damaging agents (Gong et al., 1999; Yuan et al., 1999; Katoh et al., 2000; Okada et al., 2002; Pediconi et al., 2003) , we tested the expression of TP63 in hepatocytes and HCC cell lines upon various stress signals. In response to UV-B, methotrexate, g-irradiation and hydrogen peroxide, no variation in TP63 expression was observed in mouse hepatocytes, whatever the TP53 status of cells (data not shown). Then, we used doxorubicin (DOX) and etoposide (ETO). DOX, one member of anthracyclin family, inhibits the topoisomerase II and induces ROS production and DNA-damage (Hortobagyi, 1997) . ETO essentially inhibits the topoisomerase II, leading to double-strand breaks in DNA (Hande, 1998) . We first treated primary cultures of mouse hepatocytes with 1 mM DOX or 10 mM ETO. TP63 expression was strongly increased by the two drugs ( Figure 1a , lanes ' þ DOX' and data not shown). The induction reached a maximum at 48 h and was stable as long as cells were maintained in primary culture (96 h). The main isoform induced corresponded to TAp63 alpha. However, a slight induction of p63 gamma isoform was sometimes detected 48 h after treatment (data not shown). A similar response was observed in hepatocytes from normal or p53-null mice, indicating that the induction of TP63 expression upon DOX or ETO treatment is p53-independent ( Figure 1a and data not shown). On the other hand, the constitutive expression of DNp63 observed in p53-null hepatocytes was not modified by drug treatment. We can exclude a role for reactive oxygen species generated by DOX treatment in the induction of TAp63 isoforms, since hydrogen peroxide has no effect on TP63 expression, as mentioned above.
The same experiments were next performed in HCC cell lines. DOX and ETO were added at 1 and 20 mM, respectively, two doses that do not result in a massive cell death. We first tested the expression of TP73 in response to treatment. None of the three isoforms we examined (TA, DN, DN 0 ) showed significant variation in their expression in Hep3B and Mahlavu cells. In HepG2 cells, neither TA nor DN 0 was modulated, whereas the expression of DN isoforms was increased in parallel with (Kartasheva et al., 2002; Vossio et al., 2002) and show that the expression of the other isoforms is not modulated by DOX or ETO. We then studied the expression of TP63. In all the three cell lines, DOX (Figure 1b ) and ETO (data not shown) induced a strong expression of TP63 gene. Upon DOX treatment, the induction of TAp63-alpha isoform was observed in all cell lines, whereas the induction of beta and gamma isoforms was only detected in Hep3B and Mahlavu (Figure 1b, lower panel) . Since no variation was observed in the level of DN, we postulated that the treatment of Hep3B and Mahlavu cells with DOX and ETO leads to the induction of the three TAp63 isoforms, alpha, beta and gamma. Western blot analysis confirmed the results obtained for alpha isoforms, that is, the increase in TAp63 alpha isoforms in the three cell lines and the absence of variation in the expression of DNp63 alpha in Hep3B cells (Figure 2) . Unfortunately, the poor quality of antibodies available for the other isoforms did not allow detecting them at the protein level.
Our results demonstrate that endogenous TAp63 can be induced at the transcriptional level in response to some forms of DNA damage. Furthermore, this induction is accompanied by an increase of the intracellular level of TAp63 alpha protein. Such an accumulation at the protein level was already reported for ectopically expressed TAp63 alpha and gamma isoforms in response to DNA-damaging agents (Katoh et al., 2000; Okada et al., 2002) , but never for endogenous p63.
Expression of p53-target genes in response to drug treatment
We used semiquantitative PCR to analyse the effect of DOX and ETO on the expression of some welldefined p53-target genes, namely WAF1/CIP1, 14-3-3s, Figure 1 Expression of TP63 gene in hepatocytes and hepatocellular carcinoma cell lines, in response to doxorubicin treatment. Cells were treated with 1 mM doxorubicin at time 0 and harvested at various times after treatment. Total RNA was extracted using Trizol Reagent (Life Technologies) according to the manufacturer's instructions. In total, 2 mg of RNA were reverse transcribed (RT), using the Superscript II enzyme (Invitrogen). Then, PCR amplification was carried out with 1/10 of RT product, 2.5 U of Taq polymerase Platinium (Invitrogen) and 0.4 mM final of primers for p63 (see Table 1 ). b-ACTIN (forward: 5 0 gTgggCCgC CCTAggCACCA3 0 , reverse: 5 0 CggTTggCCTTAgggTTCAgggggg3 0 ) and HPRT (forward: 5 0 AgCgCAAgTTgAATCTgC3 0 , reverse: 5 0 AgCgACAATCTACCAgAg3 0 ) were used as human and mouse standards, respectively. PCR products were analysed by electrophoresis on a 1.5-2% agarose gel. (a) RNA was extracted from primary culture of hepatocytes from p53wt or p53À/À mice, 48 h after treatment; (b) RNA was extracted from the HCC cell lines HepG2 (p53wt), Mahlavu (p53R249S) and Hep3B (p53À/À), 24 or 48 h after treatment. p63, TA, DN, a, b and g refer to the amplification of all p63 isoforms, or to the specific amplification of TA, DN, a, b and g isoforms, respectively; DOX, doxorubicin, control, nontreated cells Figure 2 Expression of TAp63 alpha and DNp63 alpha isoforms in hepatocellular carcinoma cell lines treated with doxorubicin. HepG2 (p53wt), Hep3B (p53À/À) and Mahlavu (p53R249S) HCC cell lines were treated with 1 mM doxorubicin and collected at 48 h. Nuclear proteins were extracted as described by Stein and coworkers (Stein et al., 1989) . In total, 100 mg of protein extract were electrophoresed on an 8.5% SDS-polyacrylamide (30 : 0.8) gel, 4 h at 40 mA constant and then transferred onto a PVDF membrane (Roche). Membrane was first incubated with the anti-p63 rabbit antibody H-129 (Santa Cruz Biotechnology), then with HRPconjugated anti-rabbit IgG goat antibodies (Jackson Immuno Research). The reaction was revealed using ECL (Amersham Bioscience). The incubation of the same membrane with an antiKu80 antibody (Serotec) was performed to standardize the loading. Positive control, 1 mg nuclear extract from Hep3B cells transfected with a eukaryotic expression vector encoding TAp63 alpha or DNp63 alpha TP63 gene expression in liver cells A Petitjean et al GADD45, PIG3 and BAX. All the five genes were found to be constitutively expressed in the three cell lines, at comparable level in wild-type p53-deficient and proficient cells (Figure 3a, lanes -DOX, Figure 3b , lanes -ETO). This suggests that a wild-type p53-independent mechanism is operational in HCC cell lines, to maintain the constitutive expression of genes that negatively regulate cell cycle proliferation or induce apoptosis. Since TAp63 is present in all the three HCC cell lines, we postulate that it could be responsible, at least in part, for the constitutive expression of these p53-target genes. The transactivation of the p53-target genes WAF1/ CIP1, BAX, MDM2, GADD45 or 14-3-3s was already reported in other cell types after overexpression of an exogenous TAp63 (Katoh et al., 2000; Dohn et al., 2001) .
When the wild-type p53 HepG2 cell line was treated with DOX or ETO, all the p53-target genes tested were induced, with the exception of BAX in response to ETO (Figure 3a, b, upper panels) . In the p53-null Hep3B cell line, the expression of WAF1/CIP1, GADD45 and PIG3 was increased upon DOX treatment and all five target genes were induced with ETO (Figure 3a , b, middle panels). Finally, in Mahlavu cells that express p53R249S, the profile was quite different. Only WAF1/ CIP1 and 14-3-3s showed an increased expression upon treatment and no difference was observed whatever the drug used (Figure 3a, b, lower panels) .
These results indicate that both doxorubicin and etoposide induced the expression of some p53-target genes, which differ from one cell line to another. This WAF1/CIP1 protein level in hepatocellular carcinoma cell lines treated with doxorubicin or etoposide. HepG2 (p53wt), Hep3B (p53À/À) and Mahlavu (p53R249S) HCC cell lines were treated with 1 mM doxorubicin or 20 mM etoposide and collected at 0, 24 or 48 h. Nuclear proteins were extracted as described by Stein et al. (1989) . In total, 30 mg of protein extract were separated on a 10% SDS-polyacrylamide gel, and transferred onto a PVDF membrane (Roche). Membrane was first incubated with the anti-p21 rabbit antibody C-19 (Santa Cruz Biotechnology), then with HRP-conjugated anti-rabbit IgG goat antibodies (Dako). The reaction was revealed using ECL (Amersham Bioscience). The incubation of the same membrane with an antiKu80 antibody (Serotec) was performed to standardize the loading could reflect differences in the chemo-sensitivity of cells. Nevertheless, each of the cell lines showed an increase in expression of at least two of the genes irrespectively of whether p53 was wild-type, mutant or absent. The expression of these target genes is not regulated by the level of DNp63 since, as mentioned above, this level did not change upon treatment (Figure 2) . A different observation was reported for keratinocytes, in which the downregulation of DN p63 is required for UV-induced apoptosis (Liefer et al., 2000) . The nature of DNAdamage as well as the cell type could explain this discrepancy. Among the target genes studied, a systematic increase in the expression of WAF1/CIP1, the main effector of the p53-dependent cell-cycle arrest at both G1/S and G2/M checkpoints, was observed with the two drugs in all cell lines. Also, the expression of 14-3-3s, another p53-target gene involved in the G2/M transition, was found increased in all treated cell lines, except in DOX-treated Hep3B cells.
Western blot analysis of p21 WAF1/CIP1 expression showed that the protein was barely detectable in any of the three cell lines in the absence of drug treatment (Figure 4) . A dramatic increase in the level of the protein was observed in HepG2 cell line upon DOX or ETO (Figure 4, upper panel) , an effect already reported with DOX in the same cell line (Lee et al., 2002) . Interestingly, after treatment p21 WAF1/CIP1 protein was also detectable in Hep3B and Mahlavu (Figure 4 , middle and lower panels, respectively). This result indicates that induction of p21 WAF1/CIP1 is independent of p53 protein status and is compatible with the hypothesis that this expression may be activated through TAp63. Based on the mRNA level, we expected a higher amount of p21 WAF1/CIP1 protein in Mahlavu cells, similar to that found in HepG2 cells. This discrepancy may reflect differences in protein stability between the two cell lines. The increased intracellular level of p21 WAF1/CIP1 protein in response to DOX and ETO could represent a mechanism by which the cell counteracts the effects of topoisomerase II inhibitors. Indeed, p21 WAF1/CIP1 protein, by inhibiting the TOPOIIa promoter (Zhu et al., 2002) , would be able to reduce the level of target enzyme and, therefore, to make the cells more resistant to topoisomerase II inhibitors.
Doxorubicin and etoposide induce different cell cycle modifications in wild-type p53 proficient and deficient cells
To further assess if the expression of p53-target genes may have physiological consequences on proliferation and survival of cells treated with DOX or ETO, we analysed cell cycle profiles and kinetics of proliferation in untreated and treated cells. In the three cell lines, DOX or ETO treatment induced profound modification in cell cycle. In wild-type p53 cells (HepG2), the cells underwent arrest in both G1 and G2 phases, with a strong depletion of cells entering the S phase (Figure 5a , b, upper panel). The kinetic of proliferation, established by using the sulphorhodamine B assay (SRB), confirmed a cell cycle arrest, with decrease of about 50% in cell number after 48 h treatment (data not shown). These results are in agreement with the presence of an active wild-type p53 in cells. In p53-mutant or p53-null cells (Mahlavu and Hep3B, respectively), only a G2 arrest was detected and the G1 peak almost completely disappeared after 48 h of treatment (Figure 5a , b, middle and lower panels). A small sub-G1 population was also detectable in Mahlavu cells, which could correspond to apoptotic cells. SRB assay showed differences in proliferation between the two cell lines. Whereas Hep3B cells exhibited a decrease similar to that of HepG2 cells, the proliferation of Mahlavu cells was found to be dramatically affected, with a 10-fold difference at 48 h between untreated and treated cells (data not shown). This could be explained by a difference in intracellular level of topoisomerase IIa or, alternatively, by the intense rate of proliferation of this cell line compared to the other ones (about three-fold more). Flow cytometry data were in agreement with the expression of the p53-target genes that we observed (Figures 3) , that is, a systematic increase of WAF1/CIP1 and 14-3-3s transcripts (except 14-3-3s in DOX-treated Hep3B cells), both genes involved in G2/M transition. They were also consistent with the cell cycle profiles previously described, for doxorubicin-treated HCC cell lines, which showed a G1 arrest in HepG2 cells and a G2/M arrest in Hep3B cells (Lee et al., 2002) .
In conclusion, we have demonstrated for the first time that TP63 gene is expressed in mouse hepatocytes and in human HCC cell lines. Moreover, our results clearly show that the promoters P1, from which TA isoforms are transcribed, and the promoter P2 used to generate DN isoforms are not activated by the same pathways in this cell type. Whereas P1 would be activated upon drug treatment, this type of signal would not be able to regulate P2. Also, in the absence of stress, the activity of these two promoters seems to be differentially regulated, according to the p53 protein status of the cell. The expression from P2 would be inhibited by the presence of wild-type p53 or mutant p53R249S, whereas the expression of TP63 from P1 promoter appears to be p53-independent, as observed in HepG2 or in Mahlavu cells. In the absence of any p53, the expression of TP63 would be possible from both P1 and P2, as observed in Hep3B cells or in p53-null mouse hepatocytes. Further investigation is necessary to understand the mechanism by which p53 negatively regulates the P2 promoter.
We also report here that expression of TA isoforms is not detectable in normal mouse hepatocytes, whereas small amount of TA mRNA is present in HCC cell lines. This could result from the transformation status of HCC cells. Alternatively, we cannot exclude that the species -human versus mouse -or the long-term culture of HCC cells, was responsible for this difference. No data allow us to favour one of these hypotheses yet. At the opposite, the expression of DN isoforms seems to be only p53-dependent.
Finally, the observation that the expression of some p53-target genes was similar in wild-type p53-deficient cells compared to the wild-type p53-proficient cells suggests that p63 could partially substitute to wild-type 
